FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

- 1								
	OMB Number:	3235-0287						
	Estimated average burden							
	hours per response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*				2. Issuer Name <b>and</b> Ticker or Trading Symbol  Clearside Biomedical, Inc. [ CLSD ]  5. Relationship of Reporting Person(s) to Issuer (Check all applicable)																
LASEZKAY GEORGE M				٦	Cicarside Divinedical, file. [ CLSD ]								X	Director			10% Ow	ner		
(Last) (First) (Middle)					3.	Date of Earliest Transaction (Month/Day/Year)								- X	Officer (below)	(give title		Other (s below)	pecify	
C/O CLEARSIDE BIOMEDICAL, INC.					01	01/08/2020									CEO					
900 NORTH POINT PARKWAY, SUITE 200																				
(Chron)				- <b> </b> 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) ALPHAI	RETTA (	GA	30005											X	Form fil	ed by One	Repor	rting Person		
					_										Form filed by More than One Reporting Person				ing	
(City)	(	(State)	(Zip)												. 0.0011					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transa: Date (Month/D					Execution Date,		Date,	, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 a			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										v	Amount (A) or (D)		Price	Transacti	Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Stock 01/0				08/20	3/2020			A		66,250 <sup>(1)</sup> A		A	\$0.00	288,250			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)  2. Convers or Exerc Price of Derivativ Security			3A. Deemed Execution Da if any (Month/Day/	ate,	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)		Date Exercisal:	ate E xercisable D		0   N		ount mber Shares		(Instr. 4)				
Stock Option (Right to Buy)	\$2.37	01/08/2020			A		198,750		(2)	O	1/08/2030	Common Stock	198	8,750	\$0.00	198,75	50	D		

## **Explanation of Responses:**

- 1. These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 8, 2021, January 8, 2022, January 8, 2023, and January 8, 2024, subject to the Reporting Person's continuous service as of each such vesting date, and subject to accelerated vesting in
- 2. One-fourth of the shares underlying this option vest on January 8, 2021 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

## Remarks:

/s/ Mark Ballantyne, Attorney-

01/10/2020

in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.